Lv63
2130 积分 2025-01-05 加入
Molecular markers or clinical end points? What is the optimal monitoring tool for low-dose rituximab in membranous nephropathy in resource-limited settings?
3小时前
待确认
Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial
3小时前
待确认
Molecular markers or clinical end points? What is the optimal monitoring tool for low-dose rituximab in membranous nephropathy in resource-limited settings?
1天前
待确认
Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population
1天前
求助中
Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol
1天前
待确认
Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach
1天前
待确认
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
1天前
待确认
Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A2 receptor antibody positive idiopathic membranous nephropathy
1天前
待确认
Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial
1天前
待确认
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy
1天前
待确认
皖公网安备34019202002308
